Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 3/18/19 → 9/5/23 |
Funding
- Kura Oncology Incorporated: $49,211.00
The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN)
- Arnold, Susanne (PI)